Thursday, 17 August 2017

TWi receives FDA approval for generic Alzheimer's drug

03 November 2014 | News | By BioSpectrum Bureau

TWi receives FDA approval for generic Alzheimer's drug

according to IMS health Aricept's US sales were approximately $78 million for the 12 months ended June 2014

according to IMS health Aricept's US sales were approximately $78 million for the 12 months ended June 2014

Singapore: FDA has given a nod to TWi pharmaceuticals ANDA for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai's Aricept 23mg. The drug is used to treat Alzheimer's disease patients.

The Taiwan-based company said in its press release that the product will be launched at the earliest in the US via its fully owned subsidiary, TWi Pharmaceuticals USA. The drug increases the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Orchard Therapeutics appoin...

Survey Box

Does Asia have more to offer to the global 3D cell culture market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls